Research progress on proteins associated with Plasmodium vivax invasion of erythrocytes

Abstract

Abstract:

Different Plasmodium species utilize different invasion pathways and specific sets of ligand-receptor interactions to exert distinct invasion behaviors of merozoites. Most studies on host cell invasion by Plasmodium have concentrated on invasion of erythrocytes. With completion of the whole-genome sequencing of P. vivax, proteins involved in erythrocyte invasion, such as the duffy binding protein, the reticulocyte binding protein, and tryptophan-rich antigens, have been identified. This review summarizes the role of these proteins in erythrocyte invasion.

Key words: Plasmodium vivax, Erythrocyte invasion, Molecular mechanism

CLC Number:

R382.311

Xin-xin ZHANG, Rui-lin CHU, Ying-hua XUAN, Yang CHENG. Research progress on proteins associated with Plasmodium vivax invasion of erythrocytes[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2018, 36(2): 161-165.

Figures/Tables 1

References 50

[1]	World Health Organization.World malaria report 2017[R]. Geneva: World Health Organization, 2017.
[2]	Guerra CA, Howes RE, Patil AP, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009[J]. PLoS Negl Trop Dis, 2010, 4(8): e774.
[3]	张丽, 丰俊, 张少森, 等. 2016年全国疟疾疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(6): 515-519.
[4]	李奔福, 蔺应学, 郭祥瑞, 等. 中缅边境疟疾流行情况调查[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(4): 261-263.
[5]	张冬梅, 潘卫庆. 我国疟疾疫苗研究进展及前景[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(5): 390-393.
[6]	徐超, 魏庆宽, 李瑾, 等. 境外输入性恶性疟原虫抗药性相关基因突变的检测[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(6): 482-488.
[7]	Michon P, Fraser T, Adams JH.Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein[J]. Infect Immun, 2000, 68(6): 3164-3171.
[8]	Ceravolo IP, Souza-Silva FA, Fontes CJ, et al. Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission[J]. Scand J Immunol, 2008, 67(3): 270-278.
[9]	King CL, Michon P, Shakri AR, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection[J]. Proc Natl Acad Sci USA, 2008, 105(24): 8363-8368.
[10]	Ntumngia FB, Richard TL, Menezes TLD, et al. A novel erythrocyte binding protein of Plasmodium vivax suggests an alternate invasion pathway into Duffy-positive reticulocytes[J]. MBio, 2016, 7(4).
[11]	Gupta ED, Anand G, Singh H, et al. Naturally acquired human antibodies against reticulocyte-binding domains of Plasmodium vivax proteins, PvRBP2c and PvRBP1a, exhibit binding-inhibitory activity[J]. J Infect Dis, 2017, 215(10): 1558-1568.
[12]	Zeeshan M, Tyagi RK, Tyagi K, et al. Host-parasite interaction: selective Pv-fam-a family proteins of Plasmodium vivax bind to a restricted number of human erythrocyte receptors[J]. J Infect Dis, 2015, 211(7): 1111-1120.
[13]	Alam MS, Zeeshan M, Mittra P, et al. Receptor specific binding regions of Plasmodium vivax tryptophan rich antigens and parasite growth inhibition activity of PvTRAg35.2[J]. Microbes Infect, 2016, 18(9): 550-558.
[14]	Cheng Y, Lu F, Wang B, et al. Plasmodium vivax GPI-anchored micronemal antigen(PvGAMA) binds human erythrocytes independent of Duffy antigen status[J]. Sci Rep, 2016, 6(6).
[15]	Baquero LA, Moreno-Pérez DA, Garzón-Ospina D, et al. PvGAMA reticulocyte binding activity: predicting conserved functional regions by natural selection analysis[J]. Parasit Vectors, 2017, 10(1): 251.
[16]	Cutbush M, Mollison PL.The Duffy blood group system[J]. Heredity (Edinb), 1950, 4(3): 383-389.
[17]	Miller LH, Mason SJ, Dvorak JA, et al. Erythrocyte receptors for(Plasmodium knowlesi) malaria: Duffy blood group determinants[J]. Science, 1975, 189(4202): 561-563.
[18]	Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes[J]. J Exp Med, 1996, 184(4): 1531-1536.
[19]	Chitnis CE, Sharma A.Targeting the Plasmodium vivax Duffy-binding protein[J]. Trends Parasitol, 2008, 24(1): 29-34.
[20]	Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax[J]. Nature, 2008, 455(7214): 757-763.
[21]	Batchelor JD, Malpede BM, Omattage NS, et al. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC[J]. PLoS Pathog, 2014, 10(1): e1003869.
[22]	Grimberg BT, Udomsangpetch R, Xainli J, et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein[J]. PLoS Med, 2007, 4(12): e337.
[23]	Woolley IJ, Hotmire KA, Sramkoski RM, et al. Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype[J]. Transfusion, 2000, 40(8): 949-953.
[24]	Gunalan K, Lo E, Hostetler JB, et al. Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans[J]. Proc Natl Acad Sci USA, 2016, 113(22): 6271-6276.
[25]	Hester J, Chan ER, Menard D, et al. De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes[J]. PLoS Negl Trop Dis, 2013, 7(12): e2569.
[26]	Neafsey DE, Galinsky K, Jiang RH, et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum[J]. Nat Genet, 2012, 44(9): 1046-1050.
[27]	Urquiza M, Patarroyo MA, Marí V, et al. Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes[J]. Peptides, 2002, 23(12): 2265-2277.
[28]	Galinski MR, Barnwell JW.Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for malaria vaccine development[J]. Parasitol Today (Regul Ed), 1996, 12(1): 20-29.
[29]	Han JH, Lee SK, Wang B, et al. Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain[J]. Sci Rep, 2016, 6: 26993.
[30]	Cantor EM, Lombo TB, Cepeda A, et al. Plasmodium vivax: functional analysis of a highly conserved PvRBP-1 protein region[J]. Mol Biochem Parasitol, 2001, 117(2): 229-234.
[31]	Burns JM Jr, Adeeku EK, Dunn PD.Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes[J]. Infect Immun, 1999, 67(2): 675-680.
[32]	Burns JM, Adeeku EK, Belk CC, et al. An unusual tryptophan-rich domain characterizes two secreted antigens of Plasmodium yoelii-infected erythrocytes[J]. Mol Biochem Parasitol, 2000, 110(1): 11-21.
[33]	Curtidor H, Ocampo M, Rodríguez LE, et al. Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes[J]. Biochem Biophys Res Commun, 2006, 339(3): 888-896.
[34]	Wang B, Lu F, Cheng Y, et al. Immunoprofiling of the tryptophan-rich antigen family in Plasmodium vivax[J]. Infect Immun, 2015, 83(8): 3083-3095.
[35]	Tyagi RK, Sharma YD.Erythrocyte binding activity displayed by a selective group of Plasmodium vivax tryptophan rich antigens is inhibited by patients′ antibodies[J]. PLoS One, 2012, 7(12): e50754.
[36]	Zeeshan M, Tyagi K, Sharma YD.CD4+ T cell response correlates with naturally acquired antibodies against Plasmodium vivax tryptophan-rich antigens[J]. Infect Immun, 2015, 83(5): 2018-2029.
[37]	Rathore S, Dass S, Kandari D, et al. Basigin interacts with Plasmodium vivax tryptophan-rich antigen PvTRAg38 as a second erythrocyte receptor to promote parasite growth[J]. J Biol Chem, 2017, 292(2): 462-476.
[38]	Alam MS, Choudhary V, Zeeshan M, et al. Interaction of Plasmodium vivax tryptophan-rich antigen PvTRAg38 with band 3 on human erythrocyte surface facilitates parasite growth[J]. J Biol Chem, 2015, 290(33): 20257-20272.
[39]	Tyagi K, Hossain ME, Thakur V, et al. Plasmodium vivax tryptophan rich antigen PvTRAg36.6 interacts with PvETRAMP and PvTRAg56.6 interacts with PvMSP7 during erythrocytic stages of the parasite[J]. PLoS One, 2016, 11(3): e0151065.
[40]	Gilson PR, Nebl T, Vukcevic D, et al. Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum[J]. Mol Cell Proteomics, 2006, 5(7): 1286-1299.
[41]	Arumugam TU, Takeo S, Yamasaki T, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen[J]. Infect Immun, 2011, 79(11): 4523-4532.
[42]	Babon JJ, Morgan WD, Kelly G, et al. Structural studies on Plasmodium vivax merozoite surface protein-1[J]. Mol Biochem Parasitol, 2007, 153(1): 31-40.
[43]	Cowman AF, Tonkin CJ, Tham WH, et al. The molecular basis of erythrocyte invasion by malaria parasites[J]. Cell Host Microbe, 2017, 22(2): 232-245.
[44]	O′Donnell RA, Saul A, Cowman AF, et al. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species[J]. Nat Med, 2000, 6(1): 91-95.
[45]	Cheng Y, Wang Y, Ito D, et al. The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax[J]. Infect Immun, 2013, 81(5): 1585-1595.
[46]	Cowman AF, Healer J, Marapana D, et al. Malaria: biology and disease[J]. Cell, 2016, 167(3): 610-624.
[47]	Cheng Y, Shin EH, Lu F, et al. Antigenicity studies in humans and immunogenicity studies in mice: an MSP1P subdomain as a candidate for malaria vaccine development[J]. Microbes Infect, 2014, 16(5): 419-428.
[48]	Healer J, Murphy V, Hodder AN, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum[J]. Mol Microbiol, 2004, 52(1): 159-168.
[49]	Maskus DJ, Królik M, Bethke S, et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum apical membrane antigen 1[J]. Sci Rep, 2016, 6: 39462.
[50]	Arévalo-Pinzón G, Bermúdez M, Hernández D, et al. Plasmodium vivax ligand-receptor interaction: PvAMA-1 domain I contains the minimal regions for specific interaction with CD71+ reticulocytes[J]. Sci Rep, 2017, 7(1): 9616.